Amazon’s $200 billion year: retail muscle, chip ambition, and a pharmacy plot twist
TL;DR
Quick Summary
- Amazon is planning about $200 billion in 2026 capex, signaling an aggressive build-out across AWS, AI infrastructure, and logistics.
- Amazon says its custom chip business is at $20+ billion annual revenue run rate, strengthening AWS’s ability to offer AI compute without living at the mercy of GPU scarcity.
- Amazon Pharmacy is adding Eli Lilly’s newly approved weight-loss pill Foundayo, pushing Amazon further into healthcare via convenience and delivery speed.
You've reached your free daily article limit (1/1).
Create a free account to get unlimited access to all articles, market insights, and more.
Register for FreeAlready have an account? Sign in
Disclaimer: KAHROS is a financial media and technology company. The Services, including any AI-generated content and articles, are for informational purposes only and do not constitute financial, legal, tax, or investment advice, nor an offer or solicitation to buy or sell any securities. Market information may be time-sensitive, incomplete, or subject to change without notice. We are not a registered broker-dealer or investment advisor. Please refer to our Terms of Service for more details.
Disclaimer: KAHROS is a financial media and technology company. The Services, including any AI-generated content and articles, are for informational purposes only and do not constitute financial, legal, tax, or investment advice, nor an offer or solicitation to buy or sell any securities. Market information may be time-sensitive, incomplete, or subject to change without notice. We are not a registered broker-dealer or investment advisor. Please refer to our Terms of Service for more details.
